Originally published by our sister publication Gastroenterology & Endoscopy News
By GEN Staff
The FDA has granted accelerated approval to seladelpar (Livdelzi, Gilead) in combination with ursodeoxycholic acid for adults with primary biliary cholangitis.
The drug, a peroxisome proliferator−activated receptor delta agonist, is approved as a monotherapy for patients who have had an inadequate response to or cannot tolerate UDCA. It is not recommended in patients with decompensated